<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20120801010471N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-08-05</date_registration>
      <primary_sponsor>Sanandaj University of Medical Sciences</primary_sponsor>
      <public_title>Comparative study of the effects of Sevoflurane and Isoflurane on bleeding rate during endoscopic surgery of nasal sinus</public_title>
      <acronym>FESS</acronym>
      <scientific_title>Comparative study of the effects of Sevoflurane and Isoflurane on bleeding rate during endoscopic surgery of nasal sinus</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2016-11-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>46</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/29492</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Crossover, Purpose: Treatment, Randomization description: Simple randomization based on random number table was done dividing patients into Isofloran and Sevofloran groups, Blinding description: The researcher and surgeon were blinded by using covered  vaporizers. The anesthetist knew the  type of volatile, filled the questionnaire was not blinded.</study_design>
      <phase>3</phase>
      <hc_freetext>Effect of sevoflurane and isoflurane on bleeding rate of functional endoscopic sinus surgery.</hc_freetext>
      <i_freetext>Intervention 1: 23 patients will be assigned to each group. Continuous clinical monitoring is performed with EKG, Pulse Oximetry, temperature, BP for every 3 minutes and Bispectral Index (A 2000 BIS_XP, aspect medical system INC, Norwood, MA, USA). The patients' height and weight in both groups will be evaluated at the beginning of the entry by similar devices and an anesthetics assistance. Subsequently, 5 minutes before initiation of induction, 5 mg / kg of ringer is administered. Then, 2 μ / kg of fentanyl, 0.15 mg / kg midazolam, 1 mg / kg lidocaine, 8 mg dexamethasone, and 10 mg of metoclopramide were injected in 5 minutes to the patients. Then, propofol at a dose of 2 mg / kg is administered for induction in 30 seconds. During induction, 100% oxygen was inducted to the patients. After the disappearance of lash reflex, a dose of 0.5 mg / kg bolus atracurium was injected for muscle relaxation in 30 seconds. Intracranial intubation is performed with spiral tube number 7 for women and 7.5 for men. After intubation, mechanical ventilation to reach End tidal is set Co2 25-35 mm / Hg with 50% O2 + N2O and the volume of 8cc / kg and I / E: 1/2 and peep: 0 and RR: 12. In isoflurane group is given 1 MAC during inhalation anesthetics' operation. Our goal is to reach MAP: 65 and HR: 85. And if MAP is lower than 60, 5 mg of Ephedrine bolus is prescribed. If MAP is more than 85, 50 micrograms of TNG will be injected. No other medicine will be prescribed. If for any reason we have to use another medicine, or change the patient's ventilation, and if the operation has an effect on the amount of bleeding, the patient is excluded from the study and at the end of the project, the paper will record the cause. During surgery, every 30 minutes, according to the amount of TOF, non-depolarizing muscle relaxation will be repeated based on narcotic BIS. Immediately after the completion of surgery, all medicines will be discontinued except oxygen, and the patient will be extubated after airway reflexes. Intervention 2: Control group: 23 patients will be assigned to this group. Continuous clinical monitoring is performed with EKG, Pulse Oximetry, temperature, BP for every 3 minutes and Bispectral Index (A 2000 BIS_XP, aspect medical system INC, Norwood, MA, USA). The patients' height and weight in both groups will be evaluated at the beginning of the entry by similar devices and an anesthetics assistance. Subsequently, 5 minutes before initiation of induction, 5 mg / kg of ringer is administered. Then, 2 μ / kg of fentanyl, 0.15 mg / kg midazolam, 1 mg / kg lidocaine, 8 mg dexamethasone, and 10 mg of metoclopramide were injected in 5 minutes to the patients. Then, propofol at a dose of 2 mg / kg is administered for induction in 30 seconds. During induction, 100% oxygen was inducted to the patients. After the disappearance of lash reflex, a dose of 0.5 mg / kg bolus atracurium was injected for muscle relaxation in 30 seconds. Intracranial intubation is performed with spiral tube number 7 for women and 7.5 for men. After intubation, mechanical ventilation to reach End tidal is set Co2 25-35 mm / Hg with 50% O2 + N2O and the volume of 8cc / kg and I / E: 1/2 and peep: 0 and RR: 12. In sevoflurane  group is given 1 MAC during inhalation anesthetics' operation. Our goal is to reach MAP: 65 and HR: 85. And if MAP is lower than 60, 5 mg of Ephedrine bolus is prescribed. If MAP is more than 85, 50 micrograms of TNG will be injected. No other medicine will be prescribed. If for any reason we have to use another medicine, or change the patient's ventilation, and if the operation has an effect on the amount of bleeding, the patient is excluded from the study and at the end of the project, the paper will record the cause. During surgery, every 30 minutes, according to the amount of TOF, non-depolarizing muscle relaxation will be repeated based on narcotic BIS. Immediately after the completion of surgery, all medicines will be discontinued except oxygen, and the patient will be extubated after airway reflexes.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All of the data Provided except private data of patients

When:
After the submission of the article in a valid journal

To whom:
This is available for any researchers who  interested in subject .

Conditions:
Any new research based on  our date with cooperation would be available .

Where to obtain:
Dr.Milad Masaeli

How to obtain:
The available data should be asked in an email to let me know how i can help with this

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Milad Masaeli</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kowsar Hospital, Pasdaran ave, Sanandaj</address>
        <city>Sanandaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>66177-13446</zip>
        <telephone>+98 87 3361 1231</telephone>
        <email>drmilmas@yahoo.com</email>
        <affiliation>Sanandaj University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Milad Masaeli</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kowsar Hospital, Pasdaran ave, Sanandaj</address>
        <city>Sanandaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>66177-13446</zip>
        <telephone>+98 87 3361 1231</telephone>
        <email>drmilmas@yahoo.com</email>
        <affiliation>Sanandaj University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Elective surgery
Patients between 18 and 60 years old
ASA 1,2</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>BMI≥30
Alchohol user
Medications that affect MAC
Communication problems
Fungal sinusitis
Nasal polyps greater than 3 (due to increased inflammation and vascularity of the vessels that both cause increasing bleeding in the surgical field and Surgery Grade Score)
Substance user</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>23 patients will be assigned to each group. Continuous clinical monitoring is performed with EKG, Pulse Oximetry, temperature, BP for every 3 minutes and Bispectral Index (A 2000 BIS_XP, aspect medical system INC, Norwood, MA, USA). The patients' height and weight in both groups will be evaluated at the beginning of the entry by similar devices and an anesthetics assistance. Subsequently, 5 minutes before initiation of induction, 5 mg / kg of ringer is administered. Then, 2 μ / kg of fentanyl, 0.15 mg / kg midazolam, 1 mg / kg lidocaine, 8 mg dexamethasone, and 10 mg of metoclopramide were injected in 5 minutes to the patients. Then, propofol at a dose of 2 mg / kg is administered for induction in 30 seconds. During induction, 100% oxygen was inducted to the patients. After the disappearance of lash reflex, a dose of 0.5 mg / kg bolus atracurium was injected for muscle relaxation in 30 seconds. Intracranial intubation is performed with spiral tube number 7 for women and 7.5 for men. After intubation, mechanical ventilation to reach End tidal is set Co2 25-35 mm / Hg with 50% O2 + N2O and the volume of 8cc / kg and I / E: 1/2 and peep: 0 and RR: 12. In isoflurane group is given 1 MAC during inhalation anesthetics' operation. Our goal is to reach MAP: 65 and HR: 85. And if MAP is lower than 60, 5 mg of Ephedrine bolus is prescribed. If MAP is more than 85, 50 micrograms of TNG will be injected. No other medicine will be prescribed. If for any reason we have to use another medicine, or change the patient's ventilation, and if the operation has an effect on the amount of bleeding, the patient is excluded from the study and at the end of the project, the paper will record the cause. During surgery, every 30 minutes, according to the amount of TOF, non-depolarizing muscle relaxation will be repeated based on narcotic BIS. Immediately after the completion of surgery, all medicines will be discontinued except oxygen, and the patient will be extubated after airway reflexes.</i_keyword>
      <i_keyword>Control group: 23 patients will be assigned to this group. Continuous clinical monitoring is performed with EKG, Pulse Oximetry, temperature, BP for every 3 minutes and Bispectral Index (A 2000 BIS_XP, aspect medical system INC, Norwood, MA, USA). The patients' height and weight in both groups will be evaluated at the beginning of the entry by similar devices and an anesthetics assistance. Subsequently, 5 minutes before initiation of induction, 5 mg / kg of ringer is administered. Then, 2 μ / kg of fentanyl, 0.15 mg / kg midazolam, 1 mg / kg lidocaine, 8 mg dexamethasone, and 10 mg of metoclopramide were injected in 5 minutes to the patients. Then, propofol at a dose of 2 mg / kg is administered for induction in 30 seconds. During induction, 100% oxygen was inducted to the patients. After the disappearance of lash reflex, a dose of 0.5 mg / kg bolus atracurium was injected for muscle relaxation in 30 seconds. Intracranial intubation is performed with spiral tube number 7 for women and 7.5 for men. After intubation, mechanical ventilation to reach End tidal is set Co2 25-35 mm / Hg with 50% O2 + N2O and the volume of 8cc / kg and I / E: 1/2 and peep: 0 and RR: 12. In sevoflurane  group is given 1 MAC during inhalation anesthetics' operation. Our goal is to reach MAP: 65 and HR: 85. And if MAP is lower than 60, 5 mg of Ephedrine bolus is prescribed. If MAP is more than 85, 50 micrograms of TNG will be injected. No other medicine will be prescribed. If for any reason we have to use another medicine, or change the patient's ventilation, and if the operation has an effect on the amount of bleeding, the patient is excluded from the study and at the end of the project, the paper will record the cause. During surgery, every 30 minutes, according to the amount of TOF, non-depolarizing muscle relaxation will be repeated based on narcotic BIS. Immediately after the completion of surgery, all medicines will be discontinued except oxygen, and the patient will be extubated after airway reflexes.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Bleeding rate on endoscopic sinus surgery. Timepoint: The measurement of the amount of bleeding is evaluated with the mass of used sterilized gases using a calibrated scale each day and the amount of blood accumulated in the suction in cc .and after 60 minutes through Grade Score, the surgeon also evaluates the amount of bleeding during the surgery. Method of measurement: Grade Assessment :  0 = No bleeding (Cadaveric conditions). 1= Slight bleeding - no suctioning required. 2= Slight bleeding - occasional suctioning required.3 = light bleeding - frequent suctioning required; bleeding threatens surgical field a few seconds after suction is removed.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Sanandaj University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-05-28</approval_date>
        <contact_name>Ethical Committee Of Kurdistan University Of Medical Science</contact_name>
        <contact_address>Pasdaran Sanandaj Kurdistan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
